Brugada Syndrome: Clinical Significance and Risk

Brugada syndrome indicates an inherited cardiac channelopathy that predisposes patients to life-threatening ventricular arrhythmias and sudden cardiac death (SCD), particularly in young males with structurally normal hearts. 1

Diagnostic Electrocardiographic Pattern

Brugada syndrome is characterized by coved ST-segment elevation ≥2 mm in leads V1 and/or V2 (positioned in the second, third, or fourth intercostal space), followed by negative T waves in right precordial leads. 1, 2 This pattern can occur:

Spontaneously (highest risk)
During fever or vagotonic states
After sodium channel blocker challenge (ajmaline, flecainide, procainamide, pilsicainide)

The Type 1 ECG pattern is the only diagnostic pattern for Brugada syndrome. 2

Clinical Implications and Risk

What This Diagnosis Means:

Sudden cardiac death risk varies dramatically by presentation:

Cardiac arrest survivors: 13.5% per year recurrence rate 2
Symptomatic patients (syncope): 3.2% per year 2
Asymptomatic patients: 1% per year 2

The syndrome predominantly affects young males (8-fold higher than females), with ventricular fibrillation occurring at mean age 41 ± 15 years, typically during rest or sleep. 2

Critical Triggers to Avoid:

Fever is the most important modifiable trigger and warrants aggressive antipyretic treatment. 1, 2 Other triggers include:

Specific medications (psychotropics, anesthetics) - see www.brugadadrugs.org
Cocaine
Excessive alcohol intake
Large meals

1, 2

Risk Stratification Algorithm

Highest Risk (requires ICD):

Prior cardiac arrest survivors
Documented spontaneous sustained VT 1, 2

Intermediate Risk (ICD should be considered):

Spontaneous Type 1 ECG pattern + history of syncope 2

Lower Risk (individualized approach):

Asymptomatic with spontaneous Type 1 pattern
Drug-induced Type 1 pattern only (very low risk if spontaneous pattern ruled out with repeated ECGs and 24-hour Holter monitoring) 3

Important Caveat on Electrophysiology Studies:

The prognostic value of programmed ventricular stimulation remains controversial and not definitively predictive of cardiac events at follow-up. 2 The 2017 AHA/ACC/HRS guidelines give only a IIb recommendation (may be considered) for EP studies in asymptomatic patients with spontaneous Type 1 pattern. 1

Genetic Testing Considerations

Genetic testing yields positive results in only 20-30% of phenotype-positive patients, with SCN5A variants accounting for most cases. 1 However:

A negative genetic test does NOT exclude Brugada syndrome (diagnosis remains clinical/ECG-based)
2-10% of healthy individuals carry rare SCN5A variants
Genetic testing may facilitate cascade screening of family members

Management Implications

ICD implantation is the only proven therapy to reduce SCD risk and is indicated for symptomatic patients. 1, 2

Quinidine may be considered as alternative therapy in patients who refuse ICD or have contraindications, though evidence is limited. 2

Epicardial ablation of abnormal right ventricular areas may eliminate the Type 1 pattern in >75% of patients and reduce VT/VF recurrence, though experience remains limited. 1

Common Pitfall:

Misdiagnosis is frequent - the characteristic ECG pattern is often misinterpreted as incomplete right bundle branch block, leading to dangerous delays in diagnosis and potentially fatal consequences. 4, 5 High precordial lead placement (second and third intercostal spaces) improves detection of Type 1 pattern. 1

What does Brugada syndrome indicate?

Have a follow-up question?